Ceftriaxone Inappropriateness for Enterococcus faecalis UTI

Enterococcal Resistance and Treatment Failure

Enterococci, including E. faecalis, are intrinsically resistant to ceftriaxone and other cephalosporins when used as monotherapy, which can lead to treatment failure and worsen patient outcomes 1
Using ceftriaxone alone for E. faecalis UTI would likely result in treatment failure and potentially worsen patient outcomes 1

Vancomycin can be considered in patients with severe beta-lactam allergies who have complicated UTIs, as recommended by the European Society of Cardiology 2

The combination of ampicillin plus ceftriaxone has shown synergy against E. faecalis in certain serious infections like endocarditis, but this combination is primarily recommended for endocarditis, not UTIs 3, 4
The American Heart Association recommends avoiding the use of ceftriaxone alone for UTI without considering the possibility of enterococcal infection, especially in patients with risk factors such as urological procedures, catheterization, or healthcare exposure 1

Assuming all gram-positive cocci will respond to cephalosporins is a clinical pitfall, as enterococci are a notable exception, according to the American College of Cardiology 1
Continuing ceftriaxone monotherapy after culture results identify E. faecalis as the causative pathogen is not recommended, as stated by the European Heart Journal 1

For complicated UTI requiring IV therapy, the European Society of Cardiology recommends IV ampicillin or ampicillin/sulbactam as the first choice, and IV vancomycin as an alternative for beta-lactam allergic patients 2
For patients with aminoglycoside-resistant strains requiring IV therapy, the American Heart Association suggests considering ampicillin plus gentamicin, and consulting infectious disease specialists for high-level aminoglycoside-resistant strains 2, 4